Fri, 29 Aug 2008 16:39:43 -0400 PeerView Press http://www.peerviewpress.com Podcast Maker v1.3.3 - http://www.lemonzdream.com/podcastmaker PeerView Press is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView Press is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes. Thought leader perspectives on current clinical advances in medicine PeerView Press is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView Press is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes. 2006 PeerView Press, 24 West 40th Street, Suite 950, New York, NY 10018 webmaster@peerviewpress.com http://podcast.peerviewpress.com/Pulmonology/podcast_Pulmonology_CME_CE_QAapp_12-6-6_144.jpg http://www.peerviewpress.com 144 144 Science & Medicine CME, Medical Education, continuing medical education, CME credits, PeerView Press, inSession, inReview, CE, Pulmonology no PeerView Press This CME activity reviews the risk factors of AAT deficiency and strategies to prevent disease progression. Strategies for improving detection and management of the disorder are also highlighted. Please be sure to view the accompanying (PDF) file for full CME/CE information. This CME activity reviews the risk factors of AAT deficiency and strategies to prevent disease progression. Strategies for improving detection and management of the disorder are also highlighted. http://podcast.peerviewpress.com/Pulmonology/PA04233FCr400.mp3 http://podcast.peerviewpress.com/Pulmonology/PA04233FCr400.mp3 Tue, 26 Aug 2008 16:29:29 -0400 Science no 00:23:51 alpha1-Antitrypsin, AAT, proteases, emphysema, bronchiectasis, panniculitis, COPD, lung cancer, augmentation, alpha-1 proteinase inhibitor (human) PeerView Press Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/Pulmonology/PA04233FCCMEinfo.pdf http://podcast.peerviewpress.com/Pulmonology/PA04233FCCMEinfo.pdf Tue, 26 Aug 2008 16:29:21 -0400 Science no 00:00:00 alpha1-Antitrypsin, AAT, proteases, emphysema, bronchiectasis, panniculitis, COPD, lung cancer, augmentation, alpha-1 proteinase inhibitor (human) PeerView Press In this program, an expert will provide an update on the latest guideline recommendations for managing asthma, particularly as they relate to the primary care setting, and discuss the implications for clinical practice. Please be sure to view the accompanying (PDF) file for full CME/CE information. In this program, an expert will provide an update on the latest guideline recommendations for managing asthma, particularly as they relate to the primary care setting, and discuss the implications for clinical practice. http://podcast.peerviewpress.com/Pulmonology/PA04191FCn176.mp3 http://podcast.peerviewpress.com/Pulmonology/PA04191FCn176.mp3 Tue, 04 Mar 2008 17:08:09 -0500 Science no 00:27:09 Asthma,EPR3,NAEPP,lung,ICS,LABA,omalizumab,IgE,FEV,allergies,allergy,anaphylaxis,nebulizers PeerView Press Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file http://podcast.peerviewpress.com/Pulmonology/PA04191FCCMECEinfo.pdf http://podcast.peerviewpress.com/Pulmonology/PA04191FCCMECEinfo.pdf Tue, 04 Mar 2008 17:08:05 -0500 Science no 00:00:00 Asthma,EPR3,NAEPP,lung,ICS,LABA,omalizumab,IgE,FEV,allergies,allergy,anaphylaxis,nebulizers PeerView Press The latest data and guidelines are applied to the control of asthma in the clinic through instructive case studies presented by Dr. Marcus. Please be sure to view the accompanying (PDF) file for full CME/CE information. The latest data and guidelines are applied to the control of asthma in the clinic through instructive case studies presented by Dr. Marcus. http://podcast.peerviewpress.com/Pulmonology/PA03462FC2p114.mp3 http://podcast.peerviewpress.com/Pulmonology/PA03462FC2p114.mp3 Mon, 03 Mar 2008 15:46:42 -0500 Science no 00:37:54 Asthma, COPD, IgE, pulmonology, EPR-3, FEV1, omalizumab, anaphylaxis PeerView Press Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file http://podcast.peerviewpress.com/Pulmonology/PA03462FC2CMEinfo.pdf http://podcast.peerviewpress.com/Pulmonology/PA03462FC2CMEinfo.pdf Mon, 03 Mar 2008 15:45:42 -0500 Science no 00:00:00 Asthma, COPD, IgE, pulmonology, EPR-3, FEV1, omalizumab, anaphylaxis PeerView Press In this CME activity, experts in the treatment of COPD present recent data on current and emerging agents used to treat this disease. Survival benefits and safety of these agents are also discussed. Current and emerging delivery systems are also highlighted. Please be sure to view the accompanying (PDF) file for full CME/CE information. In this CME activity, experts in the treatment of COPD present recent data on current and emerging agents used to treat this disease. Survival benefits and safety of these agents are also discussed. Current and emerging delivery systems are also highlighted. http://podcast.peerviewpress.com/Pulmonology/PA04161FCr358.mp3 http://podcast.peerviewpress.com/Pulmonology/PA04161FCr358.mp3 Wed, 20 Feb 2008 15:52:30 -0500 Science no 00:24:35 COPD, chronic obstructive pulmonary disease, bronchitis, anticholinergics, short-acting beta-agonists, long-acting beta-agonist, beta adrenoceptor agonists, albuterol, levabuterol, ipratropium bromide PeerView Press Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file http://podcast.peerviewpress.com/Pulmonology/PA04161FCCMEinfo.pdf http://podcast.peerviewpress.com/Pulmonology/PA04161FCCMEinfo.pdf Wed, 20 Feb 2008 15:52:02 -0500 Science no 00:00:00 COPD, chronic obstructive pulmonary disease, bronchitis, anticholinergics, short-acting beta-agonists, long-acting beta-agonist, beta adrenoceptor agonists, albuterol, levabuterol, ipratropium bromide PeerView Press In this program, an expert will discuss how to diagnose, monitor, and treat patients with difficult-to-control asthma. Patient scenarios are used to illustrate how to apply current evidence and latest treatment guidelines to everyday practice. Please be sure to view the accompanying (PDF) file for full CME/CE information. In this program, an expert will discuss how to diagnose, monitor, and treat patients with difficult-to-control asthma. Patient scenarios are used to illustrate how to apply current evidence and latest treatment guidelines to everyday practice. http://podcast.peerviewpress.com/Pulmonology/PA03778FCp131.mp3 http://podcast.peerviewpress.com/Pulmonology/PA03778FCp131.mp3 Wed, 09 Jan 2008 16:35:33 -0500 Science no 00:24:47 Asthma, pulmonology PeerView Press Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file http://podcast.peerviewpress.com/Pulmonology/PA03788FCCMEinfo.pdf http://podcast.peerviewpress.com/Pulmonology/PA03788FCCMEinfo.pdf Wed, 09 Jan 2008 16:35:30 -0500 Science no 00:00:00 CME, Medical Education, continuing medical education, CME credits, PeerView Press, inSession, inReview, CE, Pulmonology PeerView Press In this program, experts present up-to-date information on optimal management of asthma. Clinical challenges in the treatment of asthma are discussed and new concepts related to asthma control are assessed. Changes in the latest asthma guidelines are summarized, as well as the step-wise algorithm for use of asthma therapies. Please be sure to view the accompanying (PDF) file for full CME/CE information. In this program, experts present up-to-date information on optimal management of asthma. Clinical challenges in the treatment of asthma are discussed and new concepts related to asthma control are assessed. Changes in the latest asthma guidelines are summarized, as well as the step-wise algorithm for use of asthma therapies. http://podcast.peerviewpress.com/Pulmonology/PA03462FC1r246.mp3 http://podcast.peerviewpress.com/Pulmonology/PA03462FC1r246.mp3 Thu, 13 Sep 2007 10:09:27 -0400 Science no 00:31:56 Asthma, NAEPP, guidelines, NHBLI, IgE, IgE-mediated asthma, allergic asthma, anti-IgE therapy, biologics therapy, omalizumab, Xolair, steroid-resistant asthma PeerView Press Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file http://podcast.peerviewpress.com/Pulmonology/PA03462FC1r246CMEinfo.pdf http://podcast.peerviewpress.com/Pulmonology/PA03462FC1r246CMEinfo.pdf Thu, 13 Sep 2007 10:09:23 -0400 Science no 00:00:00 Asthma, NAEPP, guidelines, NHBLI, IgE, IgE-mediated asthma, allergic asthma, anti-IgE therapy, biologics therapy, omalizumab, Xolair, steroid-resistant asthma PeerView Press In this interactive activity, an expert in the management of pulmonary arterial hypertension (PAH) presents three cases, by examining criteria that establish clinical status and the diagnosis of PAH. In addition, clinical-trial data are presented regarding the efficacy and safety of available and emerging therapies for this condition. Please be sure to view the accompanying (PDF) file for full CME/CE information. In this interactive activity, an expert in the management of pulmonary arterial hypertension (PAH) presents three cases, by examining criteria that establish clinical status and the diagnosis of PAH. In addition, clinical-trial data are presented regarding the efficacy and safety of available and emerging therapies for this condition. http://podcast.peerviewpress.com/Pulmonology/PA03751FCp115.mp3 http://podcast.peerviewpress.com/Pulmonology/PA03751FCp115.mp3 Wed, 15 Aug 2007 16:56:19 -0400 Science no 00:54:28 6-minute–walk distance, Ambrisentan, Bosentan, Cardiac catheterization,Echocardiography,endothelin-receptor antagonists,Epoprostenol,Hypertension, pulmonary arterial,Iloprost,Phosphodiesterase inhibitor,Prostacyclin,Raynaud’s phenomenon,Scleroderma PeerView Press Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file http://podcast.peerviewpress.com/Pulmonology/PA03751FCCMEp115.mp3 http://podcast.peerviewpress.com/Pulmonology/PA03751FCCMEp115.pdf Wed, 15 Aug 2007 16:56:11 -0400 Science no 00:00:00 6-minute–walk distance, Ambrisentan, Bosentan, Cardiac catheterization,Echocardiography,endothelin-receptor antagonists,Epoprostenol,Hypertension, pulmonary arterial,Iloprost,Phosphodiesterase inhibitor,Prostacyclin,Raynaud’s phenomenon,Scleroderma PeerView Press In this CME/CE activity, an expert in the treatment of chronic obstructive pulmonary disease (COPD) discusses the role of the primary care physician in the diagnosis, screening, and treatment of this condition. Strategies for diagnosis and screening will be addressed as well as treatment options and future therapies for the management of COPD. Please be sure to view the accompanying (PDF) file for full CME/CE information. In this CME/CE activity, an expert in the treatment of chronic obstructive pulmonary disease (COPD) discusses the role of the primary care physician in the diagnosis, screening, and treatment of this condition. Strategies for diagnosis and screening will be addressed as well as treatment options and future therapies for the management of COPD. http://podcast.peerviewpress.com/Pulmonology/PA03395FCn160.mp3 http://podcast.peerviewpress.com/pulmonology/PA03395FCn160.mp3 Thu, 29 Mar 2007 17:43:41 -0400 Science no 00:27:31 COPD, chronic obstructive pulmonary disease, emphysema, bronchitis, bronchiectasis, asthma PeerView Press Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/Pulmonology/PA03395FCCMEInfo.pdf http://podcast.peerviewpress.com/pulmonology/PA03395FCCMEinfo.pdf Thu, 29 Mar 2007 17:43:30 -0400 Science no 00:00:00 COPD, chronic obstructive pulmonary disease, emphysema, bronchitis, bronchiectasis, asthma PeerView Press In this activity, experts discuss strategies for optimizing disease control in IgE-mediated asthma. Goals of asthma therapy and current challenges in the management of asthma are reviewed, efficacy and safety data from studies evaluating anti-IgE therapy in patients with asthma are discussed, current guidelines for asthma therapy and the role of biologics in the management of this disease are assessed, and practical recommendations for optimal management of IgE-mediated asthma are provided. Please be sure to view the accompanying (PDF) file for full CME/CE information. In this activity, experts discuss strategies for optimizing disease control in IgE-mediated asthma. Goals of asthma therapy and current challenges in the management of asthma are reviewed, efficacy and safety data from studies evaluating anti-IgE therapy in patients with asthma are discussed, current guidelines for asthma therapy and the role of biologics in the management of this disease are assessed, and practical recommendations for optimal management of IgE-mediated asthma are provided. http://podcast.peerviewpress.com/Pulmonology/PA02102FCinR124.mp3 http://podcast.peerviewpress.com/pulmonology/PA02102FCinR124.mp3 Fri, 16 Jun 2006 15:11:31 -0400 Science no 00:25:14 Asthma, IgE-mediated asthma, allergic asthma, IgE, anti-IgE antibodies, anti-IgE therapy, omalizumab, biologic therapy PeerView Press Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/Pulmonology/PA02102FCCMEinfo.pdf http://podcast.peerviewpress.com/pulmonology/PA02102FCCMEinfo.pdf Fri, 16 Jun 2006 15:11:07 -0400 Science no 00:00:00 Asthma, IgE-mediated asthma, allergic asthma, IgE, anti-IgE antibodies, anti-IgE therapy, omalizumab, biologic therapy